ELAN Stock Analysis: Elanco Animal Health | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 11.762m USD | 12M Return: 8.2% | US28414H1032 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 116M
EPS Trend: 54.0%
Qual. Beats: 2
Rev. Trend: 86.3%
Qual. Beats: 6
Warnings
Tailwinds
Seasonality 8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elanco Animal Health (NYSE: ELAN) is a global animal health company that develops, manufactures, and markets pharmaceutical products across two core segments: companion animals (pets) and production animals (livestock such as cattle, swine, and poultry). Founded in 1954 and headquartered in Indianapolis, Indiana, the company sells its products through third-party distributors and independent retailers, as well as directly to veterinarians and farm animal producers.
The pet health portfolio spans parasiticides, vaccines, and therapeutics under well-known brands such as Seresto, K-9 Advantage, Advantix, Credelio, Interceptor Plus, and Galliprant. The farm animal portfolio includes medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes marketed under brands such as Rumensin, Baytril, Experior, Maxiban, and AviPro.
Elanco operates within the GICS Health Care / Pharmaceuticals sub-industry and went public on the NYSE in September 2018. The animal health pharmaceuticals space is a specialized, high-margin segment of the broader pharmaceutical industry, with relatively few major global players serving both the companion-animal veterinary channel and the livestock production channel.
- Pet parasiticide competition erodes Seresto and Credelio pricing
- Cattle and swine cycle weakness pressures farm animal revenue
- Bayer Animal Health integration elevates debt and interest expense
| Net Income: -199.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.21 > 1.0 |
| NWC/Revenue: 38.75% < 20% (prev 49.55%; Δ -10.81% < -1%) |
| CFO/TA 0.05 > 3% & CFO 617.0m > Net Income -199.0m |
| Net Debt (3.39b) to EBITDA (774.0m): 4.38 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (505.9m) vs 12m ago 1.16% < -2% |
| Gross Margin: 52.59% > 18% (prev 42.98%; Δ 9.61% > 0.5%) |
| Asset Turnover: 36.77% > 50% (prev 32.63%; Δ 4.14% > 0%) |
| Interest Coverage Ratio: 0.31 > 6 (EBIT TTM 81.0m / Interest Expense TTM 259.0m) |
| A: 0.14 (Total Current Assets 3.80b - Total Current Liabilities 1.85b) / Total Assets 13.6b |
| B: -0.15 (Retained Earnings -2.07b / Total Assets 13.6b) |
| C: 0.01 (EBIT TTM 81.0m / Avg Total Assets 13.7b) |
| D: 0.94 (Book Value of Equity 6.59b / Total Liabilities 6.97b) |
| Altman-Z'' = 1.47 = BB |
| DSRI: 0.93 (Receivables 1.15b/1.10b, Revenue 5.02b/4.48b) |
| GMI: 0.82 (GM 42.98% / 52.59%) |
| AQI: 0.97 (AQ_t 0.62 / AQ_t-1 0.64) |
| SGI: 1.12 (Revenue 5.02b / 4.48b) |
| TATA: -0.06 (NI -199.0m - CFO 617.0m) / TA 13.6b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of October 20, 2026, the stock is trading at USD 23.49 with a total of 2,900,342 shares traded. Over the past week, the price has changed by +4.12%, over one month by +4.73%, over three months by -6.56% and over the past year by +8.15%.
Current recommended Stop Loss: 22.50 (which is 4.2% or 1.4 ATR below the current price).
Elanco Animal Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ELAN.
- StrongBuy: 10
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.9 | 31.3% |
P/E Forward = 17.3611
P/S = 2.343
P/B = 1.7117
P/EG = 4.0421
Revenue TTM = 5.02b USD
EBIT TTM = 81.0m USD
EBITDA TTM = 774.0m USD
Long Term Debt = 3.85b USD (from longTermDebt, last quarter)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 3.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.39b USD (calculated: Debt 3.92b - CCE 530.0m)
Enterprise Value = 15.2b USD (11.8b + Debt 3.92b - CCE 530.0m)
Interest Coverage Ratio = 0.31 (Ebit TTM 81.0m / Interest Expense TTM 259.0m)
EV/FCF = 39.97x (Enterprise Value 15.2b / FCF TTM 379.0m)
FCF Yield = 2.50% (FCF TTM 379.0m / Enterprise Value 15.2b)
FCF Margin = 7.55% (FCF TTM 379.0m / Revenue TTM 5.02b)
Net Margin = -3.96% (Net Income TTM -199.0m / Revenue TTM 5.02b)
Gross Margin = 52.59% ((Revenue TTM 5.02b - Cost of Revenue TTM 2.38b) / Revenue TTM)
Gross Margin QoQ = 58.33% (prev 57.26%)
Tobins Q-Ratio = 1.12 (Enterprise Value 15.2b / Total Assets 13.6b)
Interest Expense / Debt = 6.61% (Interest Expense 259.0m / Debt 3.92b)
Taxrate = 3.57% (2.00m / 56.0m)
NOPAT = 78.1m (EBIT 81.0m * (1 - 3.57%))
Current Ratio = 2.05 (Total Current Assets 3.80b / Total Current Liabilities 1.85b)
Debt / Equity = 0.59 (Debt 3.92b / totalStockholderEquity, last quarter 6.59b)
Debt / EBITDA = 4.38 (Net Debt 3.39b / EBITDA 774.0m)
Debt / FCF = 8.94 (Net Debt 3.39b / FCF TTM 379.0m)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.46% (Net Income -199.0m / Total Assets 13.6b)
RoE = -3.02% (Net Income TTM -199.0m / Total Stockholder Equity 6.60b)
RoCE = 0.78% (EBIT 81.0m / Capital Employed (Equity 6.60b + L.T.Debt 3.85b))
RoIC = 0.68% (NOPAT 78.1m / Invested Capital 11.5b)
WACC = 9.45% (E(11.8b)/V(15.7b) * Re(10.48%) + D(3.92b)/V(15.7b) * Rd(6.61%) * (1-Tc(0.04)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.28 | Cagr: 0.88%
[DCF] Terminal Value 72.60% ; FCFF base≈369.4m ; Y1≈391.7m ; Y5≈462.7m
[DCF] Fair Price = 5.19 (EV 5.98b - Net Debt 3.39b = Equity 2.59b / Shares 499.4m; r=9.45% [WACC]; 5y FCF grow 6.76% → 2.50% )
EPS Correlation: 54.05 | EPS CAGR: 4.89% | SUE: 2.33 | # QB: 2
Revenue Correlation: 86.35 | Revenue CAGR: 4.45% | SUE: 1.80 | # QB: 6
EPS current Quarter (2026-09-30): EPS=0.21 | Chg30d=+0.15% | Revisions=+62% | Analysts=12
EPS current Year (2026-12-31): EPS=1.14 | Chg30d=+0.10% | Revisions=+40% | GrowthEPS=+20.9% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=1.29 | Chg30d=+0.17% | Revisions=+50% | GrowthEPS=+13.3% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +72% (up=14, down=1)